MX2022010884A - Agentes terapéuticos y conjugados de estos. - Google Patents
Agentes terapéuticos y conjugados de estos.Info
- Publication number
- MX2022010884A MX2022010884A MX2022010884A MX2022010884A MX2022010884A MX 2022010884 A MX2022010884 A MX 2022010884A MX 2022010884 A MX2022010884 A MX 2022010884A MX 2022010884 A MX2022010884 A MX 2022010884A MX 2022010884 A MX2022010884 A MX 2022010884A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- class
- sub
- formula
- conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente descripción proporciona una clase de conjugados con la fórmula general (X), una clase de derivados de agonistas de TLR9, tales como la fórmula (I), (XX) y (XXI), determinados diastereómeros de agonistas de STING, una clase de derivados de agonistas de STING, tales como la fórmula (XXVIV), una clase de compuestos heterocíclicos con la fórmula general (II), una clase de compuestos heterocíclicos con la fórmula general (III), tal como se definen en el presente documento. En el presente documento se definen A1, A2, T, Z1, Z2, Z3, b1 y b2 en la fórmula (X). El conjugado proporciona propiedades únicas que se basan en las propiedades de los agentes terapéuticos que forman parte del conjugado. También se proporcionan métodos de síntesis y uso de compuestos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062986223P | 2020-03-06 | 2020-03-06 | |
| US202063062503P | 2020-08-07 | 2020-08-07 | |
| PCT/US2021/021117 WO2021178818A2 (en) | 2020-03-06 | 2021-03-05 | Therapeutic agents and conjugates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010884A true MX2022010884A (es) | 2022-12-02 |
Family
ID=77613835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010884A MX2022010884A (es) | 2020-03-06 | 2021-03-05 | Agentes terapéuticos y conjugados de estos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240066133A1 (es) |
| EP (1) | EP4114417A4 (es) |
| JP (1) | JP7885125B2 (es) |
| KR (1) | KR20220150356A (es) |
| CN (1) | CN115427051B (es) |
| AU (1) | AU2021231864A1 (es) |
| CA (1) | CA3169880A1 (es) |
| MX (1) | MX2022010884A (es) |
| TW (1) | TW202144011A (es) |
| WO (1) | WO2021178818A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4653017A1 (en) * | 2023-01-18 | 2025-11-26 | Tyligand Bioscience (Shanghai) Limited | Antibody-drug conjugate and use thereof |
| IL322523A (en) * | 2023-02-28 | 2025-10-01 | Eisai R&D Man Co Ltd | Anti-PSMA antibodies, conjugates and methods of use |
| CN117924253A (zh) * | 2023-08-17 | 2024-04-26 | 厦门大学 | 谷氨酸尿素类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物 |
| WO2026035986A1 (en) | 2024-08-07 | 2026-02-12 | Bighat Biosciences, Inc. | Humanized anti-cdh17 antibodies and use of the same |
| WO2026044149A2 (en) * | 2024-08-21 | 2026-02-26 | Eisai R&D Management Co., Ltd. | Synthesis of drug-linker combinations for antibody-drug conjugates |
| WO2026043922A1 (en) * | 2024-08-21 | 2026-02-26 | Illumina, Inc. | Modified nucleotides and related methods for nanopore sequencing |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4169944A1 (en) | 2014-03-14 | 2023-04-26 | Biomolecular Holdings LLC | Process for preparing hybrid immunoglobulin containing non-peptidyl linkage |
| US20170095573A1 (en) | 2014-06-02 | 2017-04-06 | Baylor Research Institute | Methods and compositions for treating allergy and inflammatory diseases |
| US10046046B2 (en) * | 2014-06-05 | 2018-08-14 | Victoria Link Limited | Amino sphingoglycolipid analogues |
| US20180296685A1 (en) | 2017-04-13 | 2018-10-18 | Tarveda Therapeutics, Inc. | Targeted constructs and formulations thereof |
| TWI808092B (zh) * | 2017-08-30 | 2023-07-11 | 中國大陸商北京軒義醫藥科技有限公司 | 作為干擾素基因調節劑之刺激劑的環狀二核苷酸 |
| WO2019051257A2 (en) * | 2017-09-11 | 2019-03-14 | Arbutus Biopharma Corporation | METHODS OF TREATING HEPATITIS B TYPE INFECTIONS |
| US10722591B2 (en) | 2017-11-14 | 2020-07-28 | Dynavax Technologies Corporation | Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof |
| CN110573184B (zh) * | 2018-02-09 | 2025-05-13 | 俄亥俄州立创新基金会 | Rna纳米结构,其制备方法和用途 |
| WO2019170912A1 (en) * | 2018-03-09 | 2019-09-12 | Lidds Ab | Bioresorbable controlled-release compositions with sting modulating molecules |
-
2021
- 2021-03-05 EP EP21763948.3A patent/EP4114417A4/en active Pending
- 2021-03-05 CA CA3169880A patent/CA3169880A1/en active Pending
- 2021-03-05 TW TW110107825A patent/TW202144011A/zh unknown
- 2021-03-05 JP JP2022551794A patent/JP7885125B2/ja active Active
- 2021-03-05 AU AU2021231864A patent/AU2021231864A1/en active Pending
- 2021-03-05 US US17/908,812 patent/US20240066133A1/en active Pending
- 2021-03-05 CN CN202180019078.6A patent/CN115427051B/zh active Active
- 2021-03-05 MX MX2022010884A patent/MX2022010884A/es unknown
- 2021-03-05 KR KR1020227034398A patent/KR20220150356A/ko active Pending
- 2021-03-05 WO PCT/US2021/021117 patent/WO2021178818A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4114417A2 (en) | 2023-01-11 |
| JP7885125B2 (ja) | 2026-07-06 |
| US20240066133A1 (en) | 2024-02-29 |
| CN115427051A (zh) | 2022-12-02 |
| CA3169880A1 (en) | 2021-09-10 |
| CN115427051B (zh) | 2026-05-08 |
| WO2021178818A3 (en) | 2021-10-28 |
| WO2021178818A2 (en) | 2021-09-10 |
| KR20220150356A (ko) | 2022-11-10 |
| TW202144011A (zh) | 2021-12-01 |
| JP2023516965A (ja) | 2023-04-21 |
| AU2021231864A1 (en) | 2022-09-08 |
| EP4114417A4 (en) | 2024-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021178818A3 (en) | Therapeutic agents and conjugates thereof | |
| CR20220371A (es) | Agonistas heterocíclicos de glp-1 | |
| MX2023001311A (es) | Agonistas heterociclicos de glp-1. | |
| DK1003504T3 (da) | Indolderivater og deres anvendelse som PCP-1-antagonister | |
| EA200201179A1 (ru) | Производные 2-аминокарбонил-9h-пурина | |
| NL300877I2 (nl) | obeticholzuur | |
| EA200500174A1 (ru) | Новые производные бензимидазола, полезные в качестве антипролиферативных агентов | |
| DE60230127D1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
| EA200100766A1 (ru) | Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов | |
| EA200200938A1 (ru) | Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение | |
| BG106013A (en) | New compounds and compositions as protease inhibitors | |
| DE60210944D1 (de) | N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten | |
| CY1106674T1 (el) | Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους | |
| DK1204654T3 (da) | Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister | |
| RU95106649A (ru) | Производные бензимидазола в качестве непептидильных антагонистов рецепторов тахикинина, способ получения, фармацевтическая композиция | |
| EA200400073A1 (ru) | Пирролопиримидины как ингибиторы протеинкиназы | |
| EA200300248A1 (ru) | Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции | |
| ATE316083T1 (de) | Adamantanderivate | |
| DE602004009200D1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
| DE60313350D1 (de) | Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer | |
| MXPA05011176A (es) | Derivados de carboxamida como agentes antidiabeticos. | |
| SE0102055D0 (sv) | New Compounds | |
| MX2024012470A (es) | Inhibidores de cinasas dependientes de ciclina 9 (cdk9) | |
| ATE424200T1 (de) | Solubilisierte topoisomerase-gift-mittel |